Anna Roskilly from Leeds presenting her work with Ian Rowe showing a lower fibrosis progression rate in nafld to cirrhosis than widely thought. #BASL2018

I will be presenting our work from @LeedsMedHealth on fibrosis progression in #NASH in parallel 1 (Room 24/25) this morning at 9.15 - come and see the impact on the development of cirrhosis #LiverMtg18 AASLD

Slow fibrosis progression rates in placebo-treated randomized controlled trial participants with NASH predict low rates of cirrhosis development. Presented by Dr Ian Rowe Ian Rowe of University of Leeds #LiverMtg18 AASLD

New funding promises extra support for people with alcohol problems news.leeds.gov.uk/new-funding-pr… #HealthyLeeds

Reserve your FREE place for the next Leeds Dual Diagnosis Network talk HEPATOLOGY AND SUBSTANCE USE by Jon McGowan & Richard Parker of Leeds Teaching Hospitals & Leeds Liver Transplant and Hepatology on the 7 Jun eventbrite.co.uk/e/hepatology-a…

New in Journal of Hepatology from my colleague Richard Parker here Leeds Teaching Hospitals and me @LeedsMedHealth with European collaborators. Outcomes after biopsy in alcohol related #liver disease - better natural history data are needed! Full paper: bit.ly/2KtHZJp

A chart showing what people actually die from vs. what people google or what’s reported in media. Quite a disparity in the #1 cause of death - heart disease cc:Trymaine Lee

How do you hug a climate scientist? Follow these simple rules and don't make it weird | First Dog on the Moon theguardian.com/commentisfree/…

The diagnosis of #NAFLD should carry important prognostic information. Ian Rowe & Richard Parker are advocating that now is the time to revise definition of #NAFLD to include only those who have developed advanced #fibrosis→jmp.sh/B6sJzdW via Nature Reviews Gastroenterology & Hepatology #NASH

NEW Comment! Ian Rowe & Richard Parker argue that, as expanded disease definitions are an important cause of waste in #healthcare, now it's time to revise the definition of #NAFLD to include only those who have developed advanced #fibrosis #fattyliver go.nature.com/2XKc5Mo

Come to poster #1250 this afternoon to learn more, tell me where we’ve gone wrong, or how we can improve the situation #LiverMtg19 12/12

This is a really important paper

apple.news/AyR0nzkAATfOKe…

"Our work identifies an elevated hepatic NADH/NAD+ ratio as a latent metabolic parameter that is shaped by human genetic variation and contributes causally to key metabolic traits and diseases" nature.com/articles/s4158…

Great to see this in Hepatology Communications doi.org/10.1002/hep4.1… fantastic collaboration and hopefully the starting point for some really interesting clinical science ⁦HEPATOLOGY Journal⁩ ⁦Leeds Liver Transplant and Hepatology⁩ aasldpubs.onlinelibrary.wiley.com/cms/asset/e23e…

#LiverTwitter- our next #VisualGIF! NAD Metabolome Is Functionally⬇️ in Pts Undergoing Liver Tx for #alcoholicliverdisease 👉aasldpubs.onlinelibrary.wiley.com/doi/10.1002/he… #VisualAbstract #openaccess #AASLDjournals AASLD HEPATOLOGY Journal Richard Parker Charles Brenner, PhD ALCHEP_UK

Ian Rowe Richard Parker Leeds Teaching Hospitals @LeedsMedHealth Journal of Hepatology Ahmed Elsharkawy Elliot Tapper Hemant Shah EASL Education EASLnews NottmBRCLiver&GI Matthew Armstrong 💙 Steven Masson Newcastle Hospitals Manuscript released from #wrro eprints.whiterose.ac.uk/148551/ #openaccess

The placebo response in #NASH, simply explained CGH tinyurl.com/dkvfxhd4 1⃣ Sampling variability explains the majority of the placebo response 2⃣Fibrosis progression in trials slower than in observational studies 3⃣Is liver biopsy a reliable endpoint? #LiverTwitter

Really important observation here that intervention can alter the natural history of alcohol related liver disease after detection

How do you interpret common noninvasive tests? AASLD #NAFLDsig The linked survey explores how NITs are used to guide patient care Please have a go at the linked survey, takes about 10 mins, and share with colleagues! tinyurl.com/3bmk595d